Buys | $0 | 0 | 0 |
Sells | $53,132,993 | 26 | 100 |
SEIDENBERG BETH C | director | 0 | $0 | 3 | $1.42M | $-1.42M |
Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR | 0 | $0 | 3 | $1.53M | $-1.53M |
Grant Sean | CHIEF FINANCIAL OFFICER | 0 | $0 | 1 | $4.69M | $-4.69M |
Fordyce Marshall | PRESIDENT AND CEO | 0 | $0 | 16 | $11.39M | $-11.39M |
Katabi Maha | director | 0 | $0 | 3 | $34.1M | $-34.1M |
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode …
Over the last 12 months, insiders at Vera Therapeutics, Inc. have bought $0 and sold $53.13M worth of Vera Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Vera Therapeutics, Inc. have bought $59.02M and sold $25.29M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 161,290 shares for transaction amount of $5M was made by Katabi Maha (director) on 2024‑01‑30.
2025-02-26 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 9,075 0.0145% | $27.65 | $250,882 | +1.02% | |
2025-02-21 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 10,613 0.0158% | $27.89 | $296,032 | -1.36% | |
2025-01-08 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 17,500 0.0275% | $41.74 | $730,535 | -20.51% | |
2024-12-18 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 17,500 0.0289% | $43.07 | $753,680 | -17.36% | |
2024-12-18 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 15,625 0.0257% | $42.98 | $671,536 | -17.36% | |
2024-12-18 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 3,772 0.006% | $41.33 | $155,883 | -17.36% | |
2024-12-11 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 17,500 0.0277% | $46.94 | $821,523 | -25.36% | |
2024-11-25 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 19,375 0.0313% | $47.98 | $929,560 | -22.70% | |
2024-11-13 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 30,625 0.048% | $49.50 | $1.52M | -24.18% | |
2024-10-28 | Sale | SEIDENBERG BETH C | director | 15,000 0.0323% | $48.03 | $720,493 | -12.63% | |
2024-10-23 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 19,375 0.0351% | $40.39 | $782,610 | +3.35% | |
2024-10-09 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 15,625 0.0239% | $38.24 | $597,568 | +4.80% | |
2024-09-25 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 22,225 0.0419% | $46.02 | $1.02M | -9.03% | |
2024-09-19 | Sale | SEIDENBERG BETH C | director | 13,823 0.0254% | $42.31 | $584,793 | -2.06% | |
2024-09-18 | Sale | SEIDENBERG BETH C | director | 2,653 0.005% | $42.01 | $111,440 | +2.06% | |
2024-09-11 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 15,625 0.0285% | $37.50 | $585,934 | +8.77% | |
2024-08-28 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 30,320 0.0555% | $36.84 | $1.12M | +10.03% | |
2024-08-21 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 14,471 0.0263% | $39.76 | $575,425 | +0.66% | |
2024-08-14 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 15,625 0.03% | $37.56 | $586,927 | +5.80% | |
2024-05-16 | Sale | Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR | 20,651 0.037% | $42.32 | $873,890 | -9.41% |
Katabi Maha | director | 2793987 4.3828% | $78.2M | 2 | 3 | +37.14% |
SEIDENBERG BETH C | director | 131553 0.2064% | $3.68M | 19 | 3 | +96.79% |
Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR | 51206 0.0803% | $1.43M | 2 | 3 | +91.54% |
Grant Sean | CHIEF FINANCIAL OFFICER | 0 0% | $0 | 4 | 1 | +48.2% |
COMMODORE CAPITAL LP | 10 percent owner | 4400000 6.9021% | $123.16M | 1 | 1 | +19.9% |
$66,492,695 | 135 | 27.65% | $2.04B | |
$831,902,292 | 108 | 9.34% | $1.58B | |
$20,297,544 | 73 | 103.06% | $1.61B | |
$11,583,737 | 45 | 49.75% | $1.75B | |
$224,267,561 | 40 | 26.78% | $2.17B |
Increased Positions | 134 | +100.75% | 13M | +25.23% |
Decreased Positions | 60 | -45.11% | 4M | -7.28% |
New Positions | 33 | New | 2M | New |
Sold Out Positions | 25 | Sold Out | 690,705 | Sold Out |
Total Postitions | 207 | +55.64% | 63M | +17.95% |
Avoro Capital Advisors Llc | $167,907.00 | 8.9% | 5.61M | +1M | +30.18% | 2024-12-31 |
Price T Rowe Associates Inc /Md/ | $131,005.00 | 6.95% | 4.38M | +437,940 | +11.12% | 2024-12-31 |
Blackrock, Inc. | $117,969.00 | 6.26% | 3.94M | +489,284 | +14.17% | 2024-12-31 |
Fmr Llc | $91,380.00 | 4.85% | 3.05M | +267,842 | +9.62% | 2024-12-31 |
Vanguard Group Inc | $88,280.00 | 4.68% | 2.95M | +369,387 | +14.32% | 2024-12-31 |
Sofinnova Investments, Inc. | $83,624.00 | 4.43% | 2.79M | 0 | 0% | 2024-12-31 |
State Street Corp | $60,649.00 | 3.22% | 2.03M | +202,545 | +11.11% | 2024-12-31 |
Commodore Capital Lp | $58,621.00 | 3.11% | 1.96M | -516,400 | -20.86% | 2024-12-31 |
Holocene Advisors, Lp | $56,148.00 | 2.98% | 1.88M | -78,565 | -4.02% | 2024-12-31 |
Samlyn Capital, Llc | $49,750.00 | 2.64% | 1.66M | +302,993 | +22.29% | 2024-12-31 |